| Identification | Back Directory | [Name]
2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(2,6-dimethyl-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]- | [CAS]
2573048-11-8 | [Synonyms]
2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(2,6-dimethyl-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]- | [Molecular Formula]
C27H28N6O2 | [MOL File]
2573048-11-8.mol | [Molecular Weight]
468.55 |
| Hazard Information | Back Directory | [Uses]
BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997)[1]. | [References]
[1] Sean T. Toenjes, et al. Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. ACS Med. Chem. Lett. 2023. https://doi.org/10.1021/acsmedchemlett.2c00523 |
|
|